用阳性与阴性症状量表(PANSS)和副反应量表(TESS)评定疗效和不良反应。
Positive and negative symptom scale (PANSS) and treatment emergent symptom scale (TESS) were used to evaluate the efficacy and side effects respectively.
用阳性与阴性症状量表(PANSS)和副反应量表(TESS)评定疗效和不良反应。
PANSS and TESS were used to assess the clinic and side effects.
在治疗前，治疗后4、8和12周末分别以阻性症状和阴性症状量表（PANSS）和副反应量表（TESS）评定疗效和副作用。
The efficiency and side effects were assessed with the postive and negative symptom scale (PANSS)and treatment emergent symptom seale (TESS) before and 4,8and 12 weekends after the treatment.
方法用奥氮平治疗首发精神分裂症32例，疗程8周；用简明精神病评定量表(BPRS)和副反应量表(TESS)评定疗效及副反应。
Method: 32 patients with first episode schizophrenia were treated with olanzapine for 8 weeks, and assessed with BPRS and TESS for the efficacy and safety.
疗效和不良反应分别用简明精神病评定量表（BPRS）和副反应量表（TESS）进行评定，并测定治疗第1，2，4，6周的稳态血药浓度。
Therapeutic efficacy was measured by BPRS and the adverse reaction was rated by TESS. Steady serum level was monitored within 1, 2, 4, 6 week.
疗程6周，采用汉密尔顿抑郁量表(HAMD)和副反应量表(tess)法，在治疗前，治疗后第1,2,4,6周，分别评定药物疗效和不良反应。
HAMD and TESS were used to assess the efficacy and side effects before the treatment and 1st week, 2nd week, 4th week and 6th week after it.
急性和迟发性放疗毒性反应分别使用临床肿瘤放射治疗组正常组织迟发性副反应的主观、客观、疗效和分析量表来记录。
Acute and late RT toxicity were scored using respectively the Radiation Therapy Oncology Group and the late Effects in Normal Tissues Subjective, Objective, Management and Analytic scale.
方法单独使用维思通治疗连续住院的首发精神分裂症12周，用BPRS和TESS量表评定疗效和副反应。
Method Patients with first-onset schizophrenia were treated with risperidone for 12 weeks, and assessed with BPRS and TESS for the efficacy and side effect.
采用异常不自主运动量表（AIMS）和简明精神病评定量表（BPRS）及副反应量表（TESS）在治疗前及治疗后1、2、4、6周末分别评定疗效及不良反应。
The efficacy and safety were assessed with AIMS, BPRS and TESS at the end of week 1,2,4 and 6.
以阳性和阴性症状量表（PANSS）评定临床疗效，以副反应量表（TESS）评定不良反应。
The efficacy was evaluated by positive and negative symptom scale(PANSS), and the side effects by treatment emergent symptom scale(TESS).
采用阳性症状量表和阴性症状量表(PANSS)以评定齐拉西酮对女性精神分裂症的疗效，采用不良反应量表(TESS)评定该药物的副反应。
The positive and negative symptom scale (PANSS) is adopted to appraise the curative effect, and the treatment emergent symptom scale (TESS) is adopted to appraise by-reaction.
方法对33例接受氯氮平治疗的精神分裂症患者进行定期门诊随访3年，并以简明精神病评定量表(BPRS)、副反应量表(TESS)进行疗效和副反应评定。
Methods 33 patients were accepted clozapine treatment only and followed 3 years by regular clinic visits. Using the BPRS, TESS to evaluate the efficacy.
用简明精神症状量表(BPRS)和药物副反应量表(TESS)评定疗效和副反应，治疗结束后随访两年。
The brief psychiatric rating scale (BPRS) was used to evaluate the effect, treatment emergent symptom scale (TESS) to evaluate side effects, and all the patients were followed up for 2 years.
用简明精神症状量表(BPRS)和药物副反应量表(TESS)评定疗效和副反应，治疗结束后随访两年。
The brief psychiatric rating scale (BPRS) was used to evaluate the effect, treatment emergent symptom scale (TESS) to evaluate side effects, and all the patients were followed up for 2 years.
应用推荐